液体活检公司Angle与阿斯利康签署新的商业协议

United Kingdom-based liquid biopsy company Angle (OTCQX:ANPCY) has signed a supplier agreement with the biopharmaceutical company AstraZeneca (NASDAQ:AZN) to tailor the existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D.

Under the agreement, Angle (OTCQX:ANPCY) will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response.

Assay development will take place in Angle's laboratories in Guildford, UK, and follows the company's development and launch of two highly sensitive and specific DDR assays in 2023, Angle (OTCQX:ANPCY) said in a statement.

The 6-month development phase is worth an initial £150,000 to Angle.

"This is Angle's second large pharma company agreement of 2024 as we look to drive a significant expansion of the pharma services business," Angle Chief Executive Officer, Andrew Newland said.